H5N1 News and Research

Latest H5N1 News and Research

ATS Labs offers testing of antimicrobial products for efficacy against H7N9 virus

ATS Labs announced today that they are pleased to offer testing of antimicrobial products for efficacy against avian influenza A (H7N9) virus. Avian influenza A (H7N9) virus, called H7N9 for short, has infected humans in China causing severe respiratory illness.

6 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.

11 Nov 2013

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

A study led by St. Jude Children's Research Hospital scientists highlights a new approach for developing a universal influenza vaccine that could protect against multiple flu strains, including deadly pandemic strains. The research appears today in the advance online edition of the scientific journal Nature Immunology.

22 Oct 2013

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide.

21 Oct 2013

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

...

10 Oct 2013

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

A new way to attack flu viruses is taking shape in laboratories at Rutgers University, where scientists have identified chemical agents that block the virus's ability to replicate itself in cell culture.

4 Oct 2013

Researcher characterises influenza A viruses in gulls and ducks

Ducks and gulls are the natural hosts of influenza A virus. Ragnhild Tønnessen's PhD research project has characterised influenza A viruses in gulls and ducks in Norway. Her discoveries may lead to a better understanding of the epidemiology and host adaptation of influenza A virus.

12 Sep 2013

Emerging H7N9 virus has potential to cause a pandemic

A new study has found that a novel avian-origin H7N9 influenza A virus, which has recently emerged in humans, attaches moderately or abundantly to the epithelium of both the upper and lower respiratory tracts.

10 Sep 2013

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.

7 Sep 2013

BiondVax: Priming with universal flu vaccine makes conventional bird flu vaccine effective against pandemic strains

BiondVax announced today that priming with universal flu vaccine before boosting with a conventional bird flu H5N1 vaccine (containing a single strain from Clade 1) resulted in mice exhibiting a significantly higher level of immunity to the strain contained in the conventional bird flu vaccine and in addition, broadened immunity to other H5N1 flu strains (from Clade 2).

27 Aug 2013

Strategy that dismantles flu viral genome in human lung cells ensures safe research

A new strategy that dismantles a viral genome in human lung cells will ensure safe research on deadly strains of influenza, say researchers from the Icahn School of Medicine at Mount Sinai.

13 Aug 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

Sir Michael Stratton, Thijn Brummelkamp and Anne Glover to speak at The EMBO Meeting 2013

Predisposition to cancer and other diseases, genetic testing, infectious proteins and ubiquitin signalling -- these are some of the topics internationally renowned speakers will tackle at The EMBO Meeting 2013 to be held in Amsterdam, the Netherlands, from 21-24 September 2013.

22 Jul 2013

Some strains of avian H7N9 influenza develop resistance to antiviral drugs

Some strains of the avian H7N9 influenza that emerged in China this year have developed resistance to the only antiviral drugs available to treat the infection, but testing for antiviral resistance can give misleading results, helping hasten the spread of resistant strains.

17 Jul 2013

H7 influenza may spillover repeatedly into humans, say scientists

The H7N9 avian flu strain that emerged in China earlier this year has subsided for now, but it would be a mistake to be reassured by this apparent lull in infections. The virus has several highly unusual traits that paint a disquieting picture of a pathogen that may yet lead to a pandemic, according to lead scientists from the National Institute of Allergy and Infectious Diseases.

10 Jul 2013

Seattle researchers map critical molecules that regulate inflammation during flu infection

The influenza virus' ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers at Seattle BioMed, along with collaborators at the University of California, San Diego School of Medicine, St. Jude Children's Research Hospital and the University of Washington, have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection.

6 Jul 2013

Study describes radiologic findings in H7N9 pneumonia

H7N9 pneumonia is characterized by imaging findings that differentiate it from other types of pneumonia, including rapidly progressive changes in the lungs and pulmonary connective tissues, according to the first study to describe radiologic findings in the disease. The results are published online in the journal Radiology.

2 Jul 2013

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

1 Jul 2013

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform.

20 Jun 2013

H5N1 News and Research

Latest H5N1 News and Research

ATS Labs offers testing of antimicrobial products for efficacy against H7N9 virus

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

Researcher characterises influenza A viruses in gulls and ducks

Emerging H7N9 virus has potential to cause a pandemic

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

BiondVax: Priming with universal flu vaccine makes conventional bird flu vaccine effective against pandemic strains

Strategy that dismantles flu viral genome in human lung cells ensures safe research

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

Sir Michael Stratton, Thijn Brummelkamp and Anne Glover to speak at The EMBO Meeting 2013

Some strains of avian H7N9 influenza develop resistance to antiviral drugs

H7 influenza may spillover repeatedly into humans, say scientists

Seattle researchers map critical molecules that regulate inflammation during flu infection

Study describes radiologic findings in H7N9 pneumonia

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

H5N1 News and Research

Latest H5N1 News and Research

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

Newsletters you may be interested in